Eltek Ltd.
20 Ben Zion Gelis Street, Petach Tikva, Israel
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
To Be Held on September 18, 2025
To our shareholders:
You are invited to attend the annual general meeting of the shareholders of Eltek Ltd. (“Eltek” or the “Company”) to be held at the Company’s offices, at 20 Ben Zion
Gelis Street, Petach Tikva, Israel, on September 18, 2025 at 10:00 A.M. Israel time, and thereafter as it may be adjourned from time to time (the “Meeting”) for the following purposes:
|
1. |
To re-elect Messrs. Yitzhak Nissan, Mordechai Marmorstein, David Rubner, Erez Meltzer and Ms. Revital Cohen-Tzemach, to the Company’s Board of Directors (the “Board”), to serve until the next annual general meeting of the
shareholders and until their successors have been duly elected and qualified;
|
|
2. |
To approve the Company’s Fourth Amended and Restated Compensation Policy, as described in the Proxy Statement;
|
|
3. |
To approve the extension of the exculpation letter granted to Mr. Yitzhak Nissan, as described in the Proxy Statement;
|
|
4. |
To approve the extension of the indemnification letter granted to Mr. Yitzhak Nissan, as described in the Proxy Statement;
|
|
5. |
To re-appoint Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent auditors for the year ending December 31, 2025 and for such additional period until the next annual general meeting of
shareholders, and to authorize the Board to approve their compensation; and
|
|
6. |
To review the Auditor’s Report and the Company’s Consolidated Financial Statements for the fiscal year ended December 31, 2024.
|
The Board has fixed the close of business on August 22, 2025, as the date for determining the holders of record of the Company’s ordinary shares, nominal value NIS 3.00 per share,
(the “Ordinary Shares”) entitled to notice of and to vote at the Meeting and any adjournments thereof.
Holders of record at the close of business on August 22, 2025 are entitled to notice of and to vote at the Meeting and any adjournments thereof. You can vote either by mailing in
your proxy or in person by attending the Meeting. Only proxies that are received at the Company’s offices at 20 Ben Zion Gelis Street, Petach Tikva, Israel, or by its transfer agent, by September 16, 2025 at 10:00 A.M. Israel time, will be deemed
received in a timely fashion and the votes therein recorded. If you attend the Meeting, you can revoke your proxy and vote your shares in person. Detailed proxy voting instructions are provided both in the proxy statement and on the enclosed proxy
card.
Pursuant to the Company’s Amended and Restated Articles of Association (the “Articles”), the quorum required for the Meeting consists of at least two
shareholders present, in person or by proxy, who hold or represent between them at least thirty-three percent (33%) of the total voting power attached to the Ordinary Shares then outstanding.
Items 1 and 5 are ordinary resolutions, which require the affirmative vote of a majority of the Ordinary Shares present and voting on the proposed resolution, in person or by
proxy. The votes of all shareholders voting on the matter will be counted.
Items 2 to 4 are special resolutions, which are submitted for our shareholders’ approval, following approval of each of (i) the Company’s Compensation Committee and (ii) the Board,
and which require the affirmative vote of a majority of the Ordinary Shares present and voting on the matter, in person or by proxy, provided that either (i) at least a majority of the Ordinary Shares voted
by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, are voted in favor of the proposed resolution; or (ii) the total number of the Ordinary Shares voted against the proposed resolution by
shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, does not exceed two percent (2%) of the outstanding voting power in the Company.
Generally, an act or transaction with a Controlling shareholder or in which a Controlling shareholder has a Personal Interest requires our shareholders’ approval every three (3)
years.
In accordance with the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on Foreign Stock Exchanges), 5760-2000 (the “Relief Regulations”), a
shareholder submitting a vote for each of Items 2 to 4 is deemed to confirm to the Company that such shareholder does not have a “Personal Interest” in such Item and is not a “Controlling Shareholder” (as such terms are defined under the Companies
Law), unless such shareholder had delivered the Company a notice in writing stating otherwise, no later than 10:00 A.M., Israel time, on September 16, 2025, to the attention of the Company’s Corporate Secretary, at the Company’s registered office, at
20 Ben Zion Gelis Street, Petach Tikva, Israel.
The review of our audited Consolidated Financial Statements for the fiscal year ended December 31, 2024 described in Item 6 does not involve a vote of our shareholders.
Further details of these matters to be considered at the Meeting are contained in the Company’s Proxy Statement furnished herewith. Copies of the resolutions to be adopted at the
Meeting will be available to any shareholder entitled to vote at the meeting for review at the Company’s offices during regular business hours.
The Board believes that our shareholders should be represented as fully as possible at the Meeting and encourages your vote. Whether or not you plan to be present, kindly complete,
date and sign the enclosed proxy card exactly as your name appears on the envelope containing this Notice and mail it promptly so that your votes can be recorded. No postage is required if mailed in the United
States. Return of your proxy does not deprive you of your right to attend the Meeting, to revoke the proxy or to vote your shares in person. All proxy instruments and powers of attorney must be received by the Company or its transfer agent no later
than 48 hours prior to the Meeting. The Company’s Proxy Statement is furnished herewith.
Joint holders of Ordinary Shares should take note that, pursuant to Article 25(e) of the Articles, the vote of the senior of joint holders of any share who tenders a vote, whether
in person or by proxy, will be accepted to the exclusion of the vote(s) of the other joint holder(s) of the share, and for this purpose seniority will be determined by the order in which the names stand in the shareholders’ register.
|
By Order of the Board of Directors,
|
|
|
|
Yitzhak Nissan
|
|
Chairman of the Board of Directors
|
YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE DATE AND SIGN THE PROXY CARD AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE FOR WHICH NO POSTAGE IS
REQUIRED IF MAILED IN THE UNITED STATES. YOU CAN LATER REVOKE YOUR PROXY, ATTEND THE MEETING AND VOTE YOUR SHARES IN PERSON. ALL PROXY INSTRUMENTS AND POWERS OF ATTORNEY MUST BE DELIVERED TO THE COMPANY OR ITS TRANSFER AGENT NO LATER THAN 48 HOURS
PRIOR TO THE MEETING.
- ii -
Eltek Ltd.
20 Ben Zion Gelis Street
Petach Tikva, Israel
ANNUAL GENERAL MEETING OF SHAREHOLDERS
To Be Held on September 18, 2025
PROXY STATEMENT
This Proxy Statement is furnished to the holders of Ordinary Shares, NIS 3.0 nominal value (the “Ordinary Shares”), of Eltek Ltd. (“Eltek” or the “Company”) in
connection with the solicitation of proxies to be voted at the annual general meeting of the Company’s shareholders to be held at the Company’s offices at 20 Ben Zion Gelis Street, Petach Tikva, Israel, on September 18, 2025 at 10:00 A.M. Israel
time, and thereafter as it may be adjourned from time to time (the “Meeting”). Our shareholders will be asked to vote upon the following matters:
|
1. |
To re-elect Messrs. Yitzhak Nissan, Mordechai Marmorstein, David Rubner, Erez Meltzer and Ms. Revital Cohen-Tzemach, to the Company’s Board of Directors (the “Board”), to serve until the next annual general meeting of the
shareholders and until their successors have been duly elected and qualified;
|
|
2. |
To approve the Company’s Fourth Amended and Restated Compensation Policy, as described in the Proxy Statement;
|
|
3. |
To approve the extension of the exculpation letter granted to Mr. Yitzhak Nissan, as described in the Proxy Statement;
|
|
4. |
To approve the extension of the indemnification letter granted to Mr. Yitzhak Nissan, as described in the Proxy Statement;
|
|
5. |
To re-appoint Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent auditors for the year ending December 31, 2025 and for such additional period until the next annual general meeting of
shareholders, and to authorize the Board to approve their compensation; and
|
|
6. |
To review the Auditor’s Report and the Company’s Consolidated Financial Statements for the fiscal year ended December 31, 2024.
|
A proxy card for use at the Meeting and a return envelope for the proxy card are enclosed. By signing the proxy card, shareholders may vote their shares at the Meeting whether or
not they attend. Upon the receipt of a properly signed and dated proxy card in the form enclosed, the shares represented thereby will be voted in accordance with the instructions of the shareholder indicated thereon. The Company knows of no other
matters to be submitted at the Meeting other than as specified in the Notice enclosed with this Proxy Statement. Shares represented by executed and unrevoked proxies will be voted. On all matters considered at the Meeting, abstentions and broker
non-votes will not be treated as either a vote “for” or “against” the matter, although they will be counted to determine if a quorum is present.
The proxy solicited hereby may be revoked at any time prior to its exercise, by the substitution with a new proxy bearing a later date or by a request for the return of the proxy
at the Meeting. All proxy instruments and powers of attorney must be delivered to the Company or its transfer agent no later than 48 hours prior to the Meeting.
The Company expects to mail this Proxy Statement and the proxy card to shareholders on or about August 24, 2025. All expenses of this solicitation will be borne by the Company. In
addition to the solicitation of proxies by mail, directors, officers and employees of the Company, without receiving additional compensation therefore, may solicit proxies by telephone, facsimile, in person or by other means. Brokerage firms,
nominees, fiduciaries and other custodians have been requested to forward proxy solicitation materials to the beneficial owners of shares of the Company held of record by such persons, and the Company will reimburse such brokerage firms, nominees,
fiduciaries and other custodians for reasonable out-of-pocket expenses incurred by them in connection therewith.
Shareholders Entitled to Vote.
Only holders of record of Ordinary Shares at the close of business on August 22, 2025 are entitled to notice of and to vote at the Meeting. The Company had 6,719,827 Ordinary
Shares issued and outstanding on August 14, 2025, each of which is entitled to one vote on each matter to be voted on at the Meeting. The Company’s Amended and Restated Articles of Association (the “Articles”) do not provide for cumulative
voting for the election of the directors or for any other purpose. The presence, in person or by proxy, of at least two shareholders of record holding at least thirty-three percent (33%) of the total voting
power attached to the Ordinary Shares then outstanding, will constitute a quorum at the Meeting.
Only holders of record of Ordinary Share as of the close of business on August 22, 2025 are entitled to notice of, and to vote at the Meeting, in person or by proxy:
|
• |
Voting in Person. If your shares are registered directly in your name with our transfer agent (i.e., you are a registered shareholder), you may attend and vote in person at the Meeting. If you are a
beneficial owner of shares registered in the name of your broker, bank, trustee or nominee (i.e., your shares are held in “street name”), you are also invited to attend the Meeting; however, in order
to vote in person at the Meeting as a beneficial owner, you must first obtain a “legal proxy” from your broker, bank, trustee or nominee, as the case may be, authorizing you to do so.
|
|
• |
Voting by Proxy. You may submit your proxy by mail by completing, signing and mailing the enclosed proxy card in the enclosed, postage-paid envelope, or, for shares held in street name, by following
the voting instructions provided by your broker, bank, trustee or nominee. The proxy must be received by our transfer agent or at our registered office in Israel by no later than 10:00 A.M. Israel time, on September 16, 2025, to be validly
included in the tally of Ordinary Shares voted at the Meeting. Upon the receipt of a properly signed and dated proxy in the form enclosed, the persons named as proxies therein will vote the Ordinary Shares represented thereby in accordance
with the instructions of the shareholder indicated thereon, or, if no direction is indicated, in accordance with the recommendations of the Board.
|
Votes Required.
Items 1 and 5 are ordinary resolutions, which require the affirmative vote of a majority of the Ordinary Shares present and voting on the proposed resolution, in person or by
proxy. The votes of all shareholders voting on the matter will be counted.
Items 2 to 4 are special resolutions, which are submitted for our shareholders’ approval, following approval of each of (i) the Company’s Compensation Committee and (ii) the Board,
and which require the affirmative vote of a majority of the Ordinary Shares present and voting on the matter, in person or by proxy, provided that either (i) at least a majority of the Ordinary Shares voted
by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, are voted in favor of the proposed resolution; or (ii) the total number of Ordinary Shares voted against the proposed resolution by
shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, does not exceed two percent (2%) of the outstanding voting power in the Company.
Generally, an act or transaction with a Controlling shareholder or in which a Controlling shareholder has a Personal Interest (as defined below) requires our shareholders’ approval
every three (3) years.
For the purposes of this Proxy Statement, “Controlling shareholder” means a person or entity that has the ability to direct the
Company’s actions. For Item 2, any person holding fifty percent (50%) or more of the outstanding voting power in the Company or of the rights to appoint the Company’s directors or the CEO is considered a Controlling shareholder, and for Items 3 and
4, any person holding twenty-five percent (25%) or more of the voting power in the Company, provided that no other person holds fifty percent (50%) or more of the outstanding voting power in the Company, or
of the rights to appoint the Company’s directors or the CEO, is considered a Controlling shareholder.
For the purposes of this Proxy Statement, “Personal Interest” means a shareholder’s personal interest in the approval of an act or a
transaction of the Company, including (i) the personal interest of such shareholder’s relative (which includes any members of his/her (or his/her spouse’s) immediate family or the spouses of any such members of his/her (or his/her spouse’s) immediate
family); and (ii) a personal interest of a body corporate in which a shareholder or any of his/her aforementioned relatives serves as a director or the chief executive officer, owns at least five percent (5%) of its issued and outstanding share
capital or its voting rights, or has the right to appoint directors or the chief executive officer, but excluding a personal interest arising solely from holding of shares in the Company or in a body corporate. In addition, under the Companies Law,
5759-1999 (the “Companies Law”) in case of a person voting by proxy for another person, Personal Interest includes the personal interest of either the proxy holder or the shareholder granting the proxy, whether the proxy holder has discretion
to vote or not.
In accordance with the Relief Regulations, a shareholder voting at the Meeting or prior thereto by means of the enclosed Proxy Card is deemed to confirm to the Company that such
shareholder does not have a Personal Interest with respect to any matter thus voted upon and that such shareholder is not a Controlling shareholder, unless such shareholder had previously delivered to the Company a written notice stating otherwise.
The review of our audited Consolidated Financial Statements for the fiscal year ended December 31, 2024, described under Item 6 does not involve a vote of our shareholders.
Security Ownership of Certain Beneficial Owners and Management.
The following table sets forth, as of August 14, 2025, to the best of the Company’s knowledge, information as to each person known to the Company to be the beneficial owner of more
than five percent (5%) of the outstanding Ordinary Shares. Except where indicated, to the best of the Company’s knowledge, based on information provided by the owners, the beneficial owners of the shares listed below have sole investment and voting
power with respect to those shares. Applicable percentage ownership in the following table is based on 6,719,827 Ordinary Shares outstanding as of August 14, 2025.
The shareholders’ holdings reflect their voting rights. The Company’s principal shareholders do not have different voting rights than other shareholders with respect to their
shares.
Name
|
|
Number of Ordinary Shares Beneficially Owned(1)
|
|
|
Percentage of Ownership (2)
|
|
Yitzhak Nissan(3)
|
|
|
165,223
|
|
|
|
2.46
|
%
|
Nistec Golan Ltd. (3)
|
|
|
3,368,502
|
|
|
|
50.13
|
%
|
(1)
|
Beneficial ownership is determined in accordance with the rules of the U.S. Securities and Exchange Commission (“SEC”) and generally includes voting or investment power with respect to
securities. Ordinary Shares relating to options or convertible notes currently exercisable or exercisable within sixty (60) days of the date of this table are deemed outstanding for computing the percentage of the person holding such
securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and
investment power with respect to all shares shown as beneficially owned by them.
|
(2)
|
The percentages shown are based on 6,719,827 Ordinary Shares issued and outstanding as of August 14, 2025.
|
(3)
|
Nistec Golan Ltd. is an Israeli private company controlled by Mr. Yitzhak Nissan. Accordingly, Mr. Yitzhak Nissan may be deemed to be the beneficial owner of the Ordinary Shares held directly
by Nistec Ltd.
|
Terms of Service and Employment of Executive Officers and Directors.
For information relating to the compensation of our named executive office-holders during or with respect to the year ended December 31, 2024, please see “Item 6. Directors, Senior
Management and Employees — B. Compensation” in our Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the SEC on April 8, 2025.
1. ELECTION OF DIRECTORS
(Item 1 on the Proxy Card)
At the Meeting, our shareholders are requested to re-elect a slate of five (5) directors to serve on the Board. Yitzhak Nissan, Mordechai Marmorstein, David Rubner, Erez Meltzer
and Ms. Revital Cohen-Tzemach have been nominated for re-election. Pursuant to the Articles, the number of directors in the Company (including the two (2) external directors) will be no less than three (3) nor more than nine (9), until otherwise
prescribed by a resolution of the shareholders. In accordance with the Companies Law, one external director, Mr. Gad Dovev, will continue in office until the end of his three (3) year term (on October 6, 2026), and the second external director, Ms.
Ilana Lurie, will continue in office until the end of her three (3) year term (on September 6, 2027).
The Companies Law provides that a nominee for a position of a director will have declared to the Company that he or she complies with the qualifications prescribed by the Companies
Law for appointment as a director or as an independent director, if applicable. All of the proposed nominees have declared to the Company that they comply with such applicable qualifications.
The Audit Committee and the Board have determined that Mordechai Marmorstein has the accounting and financial expertise required under the Companies Law and the Relief Regulations
necessary to serve as an independent director beyond the maximal nine (9) year period (comprised of three (3) three (3)-year periods) as set forth in the Companies Law, and therefore Mr. Marmorstein is nominated to be re-elected as an independent
director.
The five (5) nominees named in this Item 1, if elected, will each hold office until the next annual general meeting of shareholders and until their respective successors are duly
elected and qualified, unless any office is vacated earlier. The Company is unaware of any reason why any nominee, if elected, should be unable to serve as a director. All nominees listed below have advised the Board that they intend to serve as
directors if elected.
Nominees for the Board of Directors
Set forth below is information about each nominee, including age, position(s) held with the Company, principal occupation, business history and other directorships held.
Name
|
Age
|
Position
|
Yitzhak Nissan
|
76
|
Chairman of the Board
|
Mordechai Marmorstein
|
78
|
Director
|
David Rubner
|
85
|
Director
|
Erez Meltzer
|
68
|
Director
|
Revital Cohen-Tzemach
|
42
|
Director
|
Yitzhak Nissan has served as the Chairman of the Board since November 2013 and is a member of our Banking Committee. He
served as our chief executive officer from October 2014 until July 2018. Mr. Nissan is the founder of Nistec Group and has served as its chief executive officer since 1985. Mr. Nissan served as a member of ILTAM (Israeli Users’ Association of
Advanced Technologies in Hi-Tech Integrated Systems) Presidential Board between 2008 and 2009 and as a Presiding Member of the Israeli Association of Electronics and Software Industries between 2012 and 2022. Mr. Nissan also established the VPs
Operations Forum, which brings thought leadership to 200 VPs of operations from diverse hi-tech companies in Israel. In 2008, Mr. Nissan received the Distinguished Industry Award from the mayor of Petach Tikva Municipality. In 2019 Mr. Nissan was
awarded a “notable person” award by the city of Petach Tikva. Mr. Nissan holds a B.Sc. degree in Electronic Engineering from the University of Buffalo, New York.
Dr. Mordechai Marmorstein has served on the Board since October 2013 and is a member of its Audit and Compensation
Committees. From 1992 to 2001, Dr. Marmorstein was the chief financial officer of Pazchim Co. Ltd. Dr. Marmorstein was also an internal auditor and accountant at Negev Phosphate Works. Dr. Marmorstein served as the chairman of Teshet (Tourist
Enterprises and Aviation Services Co. Ltd.), a subsidiary of El-Al, the Israeli national airline, from 1999 to 2000. Dr. Marmorstein holds a B.A. degree in Economics, an M.A. degree in Contemporary Jewry Studies and a Ph.D. in Jewish History Studies,
all from Bar-Ilan University.
David Rubner has served on the Board since October 2013. Mr. Rubner is the chairman and chief executive officer of
Rubner Technology Ventures Ltd. Previously, he was a partner in Hyperion Israel Advisors Ltd., a venture capital firm. During the years 1991 to 2000, Mr. Rubner was the president and chief executive officer of ECI Telecom Ltd. (“ECI”). Prior
to that, Mr. Rubner held several senior positions within ECI. Before joining ECI, Mr. Rubner was a senior engineer in the Westinghouse Research Laboratories in Pittsburgh, Pennsylvania. Mr. Rubner served on the boards of Check Point Software Ltd.,
Radware Ltd., Telemessage International Ltd., Koor Industries Ltd., Lipman Industries Ltd. and a number of private companies. He also serves on the boards of trustees and executive council of Shaare Zedek Hospital and Jerusalem College of Technology.
Mr. Rubner holds a B.Sc. (Hons) degree in engineering from Queen Mary College, University of London and an M.S. degree from Carnegie Mellon University. Mr. Rubner was awarded 14 U.S. Patents and was the recipient of the Israeli Industry Prize for
1995.
Erez Meltzer has served as on the Board since 2009, including as its Chairman
from 2011 to 2013. Mr. Meltzer was the Executive Chairman of Hadassah Medical Center from 2014 until the end of 2020. He is currently the CEO and BOD member of Nano-x Imaging Ltd. Mr. Meltzer also serves as a director of Hadasit Bio Holding (HBL)
Ltd., Mentfield Ltd. Capital Nature Ltd., GEM Pharma Ltd., Atlasense Ltd., Supplant Ltd., Tevel Aerobotics Technologies Ltd., Xenia Ltd. and Rivulis (Plastro) Ltd. From 2008 to 2013, Mr. Meltzer served as the Chief Executive Officer of Gadot Chemical
Tankers & Terminals Ltd. From 2006 to 2007, Mr. Meltzer served as the Chief Executive Officer of Africa Israel Group. From 2002 to 2006, Mr. Meltzer served as the President and Chief Executive Officer of Netafim Ltd. From 1999 to 2001, Mr.
Meltzer served as the President and Chief Executive Officer of CreoScitex. Mr. Meltzer is a teaching Professor on Crisis Management at the Tel Aviv University since 2008. Mr. Meltzer served as a colonel in the Israeli Defense Forces – Armored Corps
(reserve). Mr. Meltzer serves as the Chairman of the Lowenstein Hospital Friends Association since 1999. Mr. Meltzer studied Economics and Business at the Hebrew University of Jerusalem and Boston University and is a graduate of the Advanced
Management Program at Harvard Business School.
Revital Cohen-Tzemach has served on the Board since 2023 and had previously attended Board meetings as a non-voting
observer (since 2022). From 2015 to 2023, Ms. Cohen-Tzemach was employed by the Company, first as a trainee in the office of the CEO, then as an assistant to the CEO, and finally as a special project manager; currently Ms. Cohen-Tzemach is not
engaged by the Company outside of her position on the Board. From 2008 until 2014, Ms. Cohen-Tzemach served as a branch manager for Halperin Optics Ltd., a major Israeli optics supplier. Ms. Cohen-Tzemach holds a B.Sc. degree in Optometry and an
Executive M.B.A. degree from Bar-Ilan University. Ms. Cohen-Tzemach is Yitzhak Nissan’s daughter.
Each director (excluding Mr. Nissan and Ms. Cohen-Tzemach) is entitled to officers’ and directors’ insurance (as may be approved by the
Company from time to time), an indemnification in the form approved by our shareholders on December 5, 2019, and an exculpation letter in the form approved by our shareholders on October 17, 2013. In addition, each director (excluding Mr. Nissan but including Ms. Cohen-Tzemach) is entitled to monetary compensation as provided in the “Permanent Amount” criteria of the Companies Regulations (Rules Regarding
Compensation and Expenses for External Directors), 5760-2000 (the “Compensation Regulations”). Each director is otherwise prohibited from receiving any other compensation, directly or indirectly, in connection with his or her services to the
Company.
Each of Mr. Nissan and Ms. Cohen-Tzemach is entitled to officers’ and directors’ insurance (as may be approved by the Compensation Committee and the Board from time to time), as
well as to an indemnification agreement and an exculpation letter in the foregoing forms (the extensions of which are further subject to the periodical approval of our shareholders; with respect to Mr. Nissan, such extensions are contingent upon the
approval of Items 2 and 3 below). Mr. Nissan is also entitled to monetary compensation, as set forth in the Amended Management Agreement by and between the Company and Nistec Ltd., which is subject to the periodical approval of our shareholders.
The Board recommends a vote FOR the election of each nominee for director named above, until the next annual general meeting of shareholders and until his or her successor has been
duly elected and qualified, without modification of terms of office.
Vote Required
The affirmative vote of the holders of a majority of the voting power represented at the Meeting, in person or by proxy, is necessary for the re-election of each of the
nominees.
2. FOURTH AMENDED AND RESTATED COMPENSATION POLICY
(Item 2 on the Proxy Card)
As required of public companies under the Companies Law, in January 2014, the Company adopted a compensation policy, setting forth the principles that govern the terms of office
and employment of the Company’s “office holders” as defined in the Companies Law. Under the Companies Law, any amendment to a public company’s compensation policy requires its shareholders’ approval. In December 2016, our shareholders approved a
new compensation policy for the Company, which was amended in September 2018 and in December 2019, amended and restated in August 2022, amended in September 2023 and amended and restated in July 2024 (the “Third Amended and Restated Compensation
Policy”). Our shareholders are requested to approve the following amendments to the Third Amended Compensation Policy (capitalized terms used and not otherwise defined below, shall have the meanings
respectively ascribed thereto in the Fourth Amended and Restated Compensation Policy (as defined below)):
|
• |
Section 4.6 (Company Car): the Car Price Ceiling amount for the Active Chairman of the Board’s company car shall be increased from NIS300,000 to NIS330,000, including 18% VAT (approximately
US$96,365); the Car Price Ceiling amount for the CEO’s company car shall be increased from NIS300,000 to NIS330,000, including 18% VAT (approximately US$96,365); the Car Price Ceiling amount for the vice presidents’ and other officers’
company car shall be increased from NIS220,000 to NIS240,000, including 18% VAT (approximately US$70,085); and the Car Price Ceiling amount for other managers’ (non-Officers) company car shall be set at NIS200,000, including 18% VAT
(approximately US$58,405).
|
This brief overview of the proposed amendments is qualified in its entirety by reference to the full text of the proposed fourth amended and restated Compensation Policy,
attached as Exhibit A hereto, in a form marked against the Third Amended and Restated Compensation Policy, as approved by our shareholders on July 8, 2024 (the “Fourth Amended and Restated
Compensation Policy”). On August 11, 2025, the Compensation Committee recommended, and on August 13, 2025, the Board accordingly resolved, to approve the Fourth Amended and Restated Compensation Policy.
At the Meeting, the Board proposes that the following resolution be adopted:
“RESOLVED, that the Fourth Amended and Restated Compensation Policy, attached to the Proxy Statement as Exhibit
A, be and hereby is, authorized and approved.”
Vote Required
The approval of this Item 2 requires the affirmative vote of a majority of the Ordinary Shares present and voting on the matter, in person or by proxy, provided that either (i) at least a majority of the Ordinary Shares voted by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, are voted in favor of the proposed resolution;
or (ii) the total number of Ordinary Shares voted against the proposed resolution by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, does not exceed two percent (2%) of the outstanding voting
power in the Company.
In accordance with the Relief Regulations, a shareholder submitting a vote for this Item 2 is deemed to confirm to the Company that such shareholder does not have a Personal
Interest in the extension of the compensation policy and is not a Controlling Shareholder, unless such shareholder has delivered the Company a notice in writing stating otherwise, no later than 10:00 A.M., Israel time, on September 16, 2025, to the
attention of the Company’s Corporate Secretary, at our registered office in Israel.
3. EXTENSION OF THE EXCULPATION LETTER GRANTED TO MR. YITZHAK NISSAN
(Item 3 on the Proxy Card)
In October 2013, our shareholders approved the Company’s undertaking to exculpate, in advance, its directors and officers from liability for damages caused as a result of a
breach of such director’s or officer’s duty of care towards the Company (the “Exculpation Letter”). Under the Exculpation Letter, the Company exempts such director or officer, to the fullest extent permitted by applicable law, from any
liability for damages caused as a result of a breach of such director’s or officer’s duty of care towards the Company, resulting from any action taken by such director or officer in good faith in his or her capacity as director or officer, as
applicable.
In accordance with the provisions of the Companies Law, an Exculpation Letter to Mr. Nissan, as our Controlling Shareholder, may be in force and effect for a maximum period of
three (3) years. In August 2022, our shareholders approved the extension of the Exculpation Letter to Mr. Nissan for a three (3) year period ending on December 31, 2025. Therefore, our shareholders are hereby requested to approve the extension of
the Exculpation Letter to Mr. Nissan for an additional three (3) year period ending on December 31, 2028.
On August 11 and 13, 2025, the Compensation Committee and the Board, respectively, approved the extension of the Exculpation Letter to Mr. Nissan.
For the avoidance of doubt, the exculpation letter which is the subject of this proposal is identical to the form that was approved by the General Meeting of Shareholders on
October 17, 2013. A copy of the exculpation letter approved by the General Meeting of Shareholders in October 2013 may be found in Annex C to the following link: https://www.sec.gov/Archives/edgar/data/1024672/000117891313002674/exhibit_99-1.htm.
The Compensation Committee and the Board believe that approval of the exculpation letter granted to Mr. Yitzhak Nissan is in the Company’s best interest and unanimously granted
its approval. Mr. Yitzhak Nissan and Ms. Cohen-Tzemach did not participate in the meetings of the Compensation Committee and the Board that granted such approval.
At the Meeting, the Board proposes that the following resolution be adopted:
“RESOLVED, to approve the extension of the Exculpation Letter to Mr. Nissan for an additional three (3) years’ period ending on December
31, 2028, as set forth in this Proxy Statement.”
The approval of this Item 3 requires the affirmative vote of a majority of the Ordinary Shares present and voting on the matter, in person or by proxy, provided that either (i)
at least a majority of the Ordinary Shares voted by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, are voted in favor of the proposed resolution; or (ii) the total number of Ordinary Shares
voted against the proposed resolution by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, does not exceed two percent (2%) of the outstanding voting power in the Company.
In accordance with the Relief Regulations, a shareholder submitting a vote for this Item 3 is deemed to confirm to the Company that such shareholder does not have a Personal
Interest in the extension of the exculpation letter and is not a Controlling Shareholder, unless such shareholder has delivered the Company a notice in writing stating otherwise, no later than 10:00 A.M., Israel time, on September 16, 2025, to the
attention of the Company’s Corporate Secretary, at our registered office in Israel.
4. EXTENSION OF THE INDEMNIFICATION LETTER GRANTED TO MR. YITZHAK NISSAN
(Item 4 on the Proxy Card)
The Companies Law and the Company’s Articles of Association authorize the Company, subject to the receipt of requisite corporate approvals, to agree in advance to indemnify
directors and officers, subject to certain conditions and limitations. In December 2019, the Company’s shareholders approved an amended indemnity agreement (the “Indemnification Letter”) granted to the Company’s directors and officers
serving from time to time in such capacity, such that the Indemnification Letter shall comply with the terms of the Companies Law.
In accordance with the provisions of the Companies Law, an Indemnification Letter to Mr. Nissan, as our Controlling Shareholder, can be in force and effect for a maximum period
of three (3) years. Therefore, our shareholders are hereby requested to approve the extension of the Indemnification Letter to Mr. Nissan for an additional three (3) years’ period ending on December 31, 2028.
On August 11 and 13, 2025, the Compensation Committee and the Board, respectively, approved the extension of the Indemnification Letter to Mr. Nissan.
For the avoidance of doubt, the indemnification letter which is the subject of this proposal is identical to the form that was approved by the General Meeting of Shareholders on
December 5, 2019. A copy of the indemnification letter approved by the General Meeting of Shareholders in December 2019 may be found in Exhibit B to the following link: https://www.sec.gov/Archives/edgar/data/1024672/000117891319002546/exhibit_99-1.htm.
The Compensation Committee and the Board believe that approval of the indemnification letter granted to Mr. Yitzhak Nissan is in the Company’s best interest and unanimously
granted its approval. Mr. Yitzhak Nissan and Ms. Cohen-Tzemach did not participate in the meetings of the Compensation Committee and the Board that granted such approval.
At the Meeting, the Board proposes that the following resolution be adopted:
“RESOLVED, to approve the extension of the Indemnification Letter to Mr. Nissan for an additional three (3) years’ period ending on
December 31, 2028, as set forth in this Proxy Statement.”
The approval of this Item 4 requires the affirmative vote of a majority of the Ordinary Shares present and voting on the matter, in person or by proxy, provided that either (i)
at least a majority of the Ordinary Shares voted by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, are voted in favor of the proposed resolution; or (ii) the total number of Ordinary Shares
voted against the proposed resolution by shareholders who are not Controlling shareholders and who do not have a Personal Interest in the matter, does not exceed two percent (2%) of the outstanding voting power in the Company.
In accordance with the Relief Regulations, a shareholder submitting a vote for this Item 4 is deemed to confirm to the Company that such shareholder does not have a Personal
Interest in the extension of the indemnification letter and is not a Controlling Shareholder, unless such shareholder has delivered the Company a notice in writing stating otherwise, no later than 10:00 A.M., Israel time, on September 16, 2025, to
the attention of the Company’s Corporate Secretary, at our registered office in Israel.
5. APPOINTMENT OF INDEPENDENT AUDITORS
(Item 5 on the Proxy Card)
The Board recommends that our shareholders approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (the “Current Auditors”) as
the Company’s independent auditors for the year ending December 31, 2025, and for such additional period, until the next annual general meeting of the shareholders.
The following table sets forth, for each of the years indicated, the audit and other fees paid to our independent registered public accountants. Prior to the appointment of our
Current Auditors, Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, served as our principal independent certified public accounting firm between December 2020 to December 2023.
|
|
|
|
|
|
|
Audit (1)
|
|
$
|
95,000
|
|
|
$
|
102,000
|
|
Audit Related Fees
|
|
$
|
35,000
|
|
|
$
|
13,500
|
|
Tax (2)
|
|
$
|
5,000
|
|
|
$
|
6,000
|
|
All other Fees (3)
|
|
$
|
5,000
|
|
|
$
|
5,000
|
|
Total
|
|
$
|
140,000
|
|
|
$
|
126,000
|
|
(1) Audit fees relate to audit services provided for each of the years shown in the table, including fees associated with the annual audit, consultations on various accounting
issues and audit services provided in connection with statutory or regulatory filings.
(2) Tax fees relate to services performed regarding tax compliance.
(3) Other fees are fees for professional services other than audit or tax related fees.
(4) In 2024, all fees listed were paid to Ernst & Young Global.
(5) In 2023, all fees listed were paid to Brightman Almagor Zohar & Co.
Pre-Approval Policies and Procedures
Our audit committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm,
(Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network for the years 2022 and 2023 and Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global for the year ending December 31, 2024). Pre-approval of an audit or
non-audit service may be given as a general pre-approval, as part of the audit committee’s approval of the scope of the engagement of our independent auditor, or on an individual basis. Any proposed services exceeding general pre-approved levels also
require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in Section 201 of the Sarbanes-Oxley Act or the rules of
the SEC, and also requires the audit committee to consider whether proposed services are compatible with the independence of the registered public accountants.
At the Meeting, the Board proposes that the following resolution be adopted:
“RESOLVED, to reappoint Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent auditors for
the fiscal year ending December 31, 2025, and for such additional period, until the next annual general meeting of shareholders, and that the Company’s Board of Directors be, and hereby is, authorized to approve their compensation.”
Vote Required
The approval of this Item 5 requires the affirmative vote of the holders of a majority of the voting power represented at the Meeting, in person or by proxy.
6. REVIEW OF AUDITOR’S REPORT AND FINANCIAL STATEMENTS
At the Meeting, the Auditor’s Report and the Company’s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2024 will be presented for review. On April
8, 2025, the Auditor’s Report and the Company’s Audited Consolidated Financial Statements were filed with the SEC under Form 20-F and appear on its website: www.sec.gov, as well as on the Company’s
website: www.nisteceltek.com. These financial statements are not a part of this Proxy Statement. This Item 6 does not involve a vote of our shareholders.
OTHER BUSINESS
The Meeting is called for the purposes set forth in the Notice accompanying this Proxy Statement. As of the date of the Notice, the Board knows of no business which will be
presented for consideration at the Meeting other than the foregoing matters.
By Order of the Board of Directors,
|
|
Yitzhak Nissan
|
Chairman of the Board of Directors
|
August 14, 2025
Exhibit A
Fourth Amended and Restated Compensation Policy